{"title": "Twenty Years of Active Bacterial Core Surveillance Technical Appendix Technical Appendix Table. Key uses and findings of Active Bacterial Core surveillance data for vaccine development, evaluation, and policy formulation* Pathogen Vaccines Key uses and findings Streptococcus pneumoniae PCV7 and PCV13 Selection of serotypes included in PCV7and PCV13 Informed ACIP recommendations for children <5 y of age (1,2) Tracking postlicensure declines in cases (3) Documented effectiveness of PCV7 (4) Monitoring incidence of non-vaccine serotypes (5) Accelerated regulatory approval of PCV13 (6) Informed ACIP recommendations for PCV13 use in immunocompromised adults and children (7,8) Neisseria meningitidis Conjugate vaccines Serogroup B vaccines", "body": "Informed ACIP recommendations for children 11-18 y of age (9) (10) (11) Informed ACIP recommendations for booster dose (12) Documented vaccine effectiveness (13) Informed ACIP infant meningococcal recommendations (14) Evaluated potential effect on serogroup B disease in United States (15) Haemophilus influenzae\n\nTracking postlicensure declines in Hib disease (16) Tracking shift toward non-Hib disease (16 Determining population groups to target (23) *ACIP, Advisory Committee on Immunization Practices; Hib, H. influenzae type b vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine."}